Anti-Cancer Technology

 

Theralase® has a separate division for Photo Dynamic Technology that develops advanced pharmaceutical products and medical devices based on proprietary non-immunosuppressive photodynamic technology, targeting key health care and oncology markets.

The strategy is to build a specialty Biopharma company by developing and commercializing new and innovative products based on its patented photodynamic compounds, lasers, drug and light delivery systems, personalized and a patient specific platform technologies.

The strategy in oncology is to continue the research & development of the anti-cancer portfolio, with transition metal – based Photodynamic Compounds ("PDC") and other new anti-cancer products, and build a commercial platform in Canada and US for clinical use worldwide.

Theralase® Bladder Cancer Clinical Study

Our anti-cancer technology has now successfully completed a Phase 1b Clinical Study for Non-Muscle Invasive Bladder Cancer ("NMIBC"). We are currently designing a Phase II Non-Muscle Invasive Bladder Cancer Clinical Study.

In the following video Dr. Girish Kulkarni MD, Surgeon-scientist affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto discusses the successful completion of this clinical study.

 

For patients or practitioners wishing to get in touch with us about our Anti-Cancer Technology please click here!

Theralase® is listed on ClinicalTrials.gov

Partners in Innovation

As part of our continuing mission to design, develop, and manufacture cutting-edge laser technologies for the treatment of pain and the eradication of disease, Theralase has partnered with individuals and groups at the following institutions and organizations:

Research Team

Theralase® has a unique combination of scientific capabilities in medical devises and small light-activated molecules discovery, design and development. This puts us in a strong position to develop the targeted innovative, science based, medical technology platforms required to meet patient needs. To increase the value of our pipeline we are not only applying the best science and technology, but also employing a comprehensive strategy to safeguard our intellectual property through patent protection.

Arkady Mandel, MD, Ph.D., D.Sc.

Interim Chief Executive Officer and Chief Scientific Officer
21+ years experience as a key founder of therapeutic uses of lasers in dermatology and other areas of clinical medicine.

Lothar Lilge

PhD, Scientific Principal Investigator
Professor in the Department of Medical Biophysics at the University of Toronto, Senior Scientist Ontario Cancer Institute, Princess Margaret Cancer Center

Manjunatha Munegowda

Research Scientist, DVM, MS, PhD
Cancer Therapy - Immunotherapy

Mark Roufaiel

Research Scientist, PhD
Immunolgy - Cardiovascular Biology

Pavel Kaspler

Research Scientist, PhD

Scientific and Medical Advisory Board

Our Scientific and Medical Advisory Board (SMAB) is comprised of international key opinion leaders and esteemed scientists with broad expertise in biomedical and clinical research, drug discovery and development, as well as, medical device engineering and manufacturing. The SMAB plays an active role in Theralase® pipeline's development with evaluation of in-licensing and partnership opportunities. The SMAB members meet regularly with the Theralase® team to maximize the chances of success of each of TLT and PDT operational divisions platform technology pipelines. Together, members of the Scientific and Medical Advisory Board provide critical evaluation and guidance of our proposed and current programmes to ensure that our research is focused and cutting-edge.

Lothar Lilge

PhD, Scientific Principal Investigator
Professor in the Department of Medical Biophysics at the University of Toronto, Senior Scientist Ontario Cancer Institute, Princess Margaret Cancer Center

Dr. Michael Jewett

MD
Professor of Surgery (Urology) at Univ. of Toronto, Surgical Oncology at Princess Margaret Cancer Centre

Dr. Michael A. O’Donnell

MD, Professor of Urology, University of Iowa
Dr. O’Donnell’s basic and clinical research has a long history of focusing on bladder immunology and bladder cancer immunotherapy

Brian C. Wilson

PhD
Dr. Wilson is a Senior Scientist and Head of the Applied Biophotonics group at Princess Margaret Cancer Centre, University Health Network and Professor in the Department of Medical Biophysics at the University of Toronto.

Ashish M. Kamat

MD, MBBS, FACS
Dr Kamat is an internationally recognized expert in urologic oncology and an authority in the management of urologic cancers.